GlassScriptPhysician profile
Glenn C Robinson
NPI 1033194592
$4,214.81
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,953 · 2020: $632 · 2021: $246 · 2022: $507 · 2023: $621 · 2024: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863 · Education: $13.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $862.95 |
| Education | $13.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,451.27 | 2019-2024 | Skyrizi, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $458.89 | 2019-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $387.92 | 2019-2024 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $375.11 | 2019-2023 | Xifaxan |
| Janssen Scientific Affairs, LLC | $356.14 | 2019-2023 | Remicade, Tremfya, Stelara |
| Pfizer INC. | $231.53 | 2019-2024 | |
| Gilead Sciences, INC. | $206.88 | 2019-2023 | |
| Celgene Corporation | $80.73 | 2022-2023 | Zeposia |
| Daiichi Sankyo INC. | $74.57 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $74.25 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.86 | 2023-2024 | Dupixent |
| Shire North American Group INC | $63.35 | 2019 | |
| Romark Laboratories, Lc | $63.24 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $52.86 | 2023 | Zerbaxa, Dificid, Recarbrio |
| Allergan, INC. | $49.84 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $46.46 | 2023 | |
| Ucb, INC. | $43.20 | 2019 | |
| Qol Medical, LLC | $39.68 | 2022-2023 | Sucraid |
| Genzyme Corporation | $39.38 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $26.14 | 2020 | |
| Dova Pharmaceuticals | $15.66 | 2019 | |
| Celltrion USA INC. | $13.85 | 2023 | Yuflyma |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.